12-15 SEPTEMBER VIRTUAL CONFERENCE

TOGETHER FOR PATIENTS

Transforming the Regulatory ecosystem in Africa DAY 4 How do patients benefit from stronger regulatory systems?







PARTNERS



DASA Inovative Pharmaceutical Association South Africa







THANK YOU FOR JOINING! Participant guide

- The 5th AfRC conference is held in English.
- All participants are muted. We encourage you to use the Q&A box to raise questions to the speakers. If a question you would like to ask has already been raised, you can also "like" that question.
- For some sessions, participants will have the opportunity to also engage with speakers through Mentimeter polls. To take part, a QR code will be displayed on screen and a link will be shared in the chat box.
- We encourage you to join all conference days.
- The 5th AfRC conference is recorded. All speaker presentations and videos will be made available on the <u>africaregulatoryconference.ifpma.org</u> website after the conference.



Présentations en anglais. Veuillez appuyer sur le globe pour avoir l'interprétation en français. Apresentações em inglês. Clique no globo para interpretação em português.



12-15 SEPTEMBER VIRTUAL CONFERENCE

Fireside Chat Session with Patients

Moderator

Paloma Tejada Associate Director, Alliance Building, IFPMA







PARTNERS



IPASA Increating Pharmaceutical Association South Africa







Fireside Chat with Patients




Paloma Tejada Associate Director, Alliance Building, IFPMA



Ms. Flavia Kyomukama Executive Director Action Group for Health, Human Rights and HIV/AIDS (AGHA) Uganda



Mrs. Nankanja Ruth Mukiibi Executive Director Sickle Cell Association of Uganda



Mr. Alex Adusei Executive Director Women's Hope Foundation and NGO advancing patient safety, women and girls human rights and gender equality



THANK YOU!







PARTNERS













Virtual coffee/tea break

We will be back at **13h40 CEST**





12-15 SEPTEMBER VIRTUAL CONFERENCE

AfRC Track 07

Moderators: **Greg Perry** – Assistant Director General - IFPMA **Zainab Aziz** – Associate Director- RA SSA Policy and Strategic Operations – Novartis


















Setting the scene for local manufacturing of health products – Needs, challenges and solutions

– Akhona Tshangela, Africa CDC

Pharmaceutical manufacturing in Africa is still nascent



Covid-19 challenge of vaccine national protectionism and delayed access in Africa highlighted need for Health security on the continent

Health product manufacturing and innovation provides a sizeable opportunity on the African continent

Large health product market in Africa provides an attractive business case



~30 bn USD market in 2022 in Africa across health products (vaccines, therapeutics, diagnostics, etc.)



Market has been growing 4% per annum (4bn USD increase) in the past 5 years



Additional ~7 bn USD growth expected in the next 5 years²

Additional benefits of localizing manufacturing and innovation



Improve health security and capacity for emergency response



Improves public health (DALY's)



Improves access and affordability



Accelerate ongoing regional harmonization initiatives to facilitate trade



Elevate technological expertise and capabilities



Facilitate economic growth

Africa CDC has set a goal to ensure 60% of health products required in Africa by 2040 are produced on the continent

Mission

To promote health security and self-reliance in Africa, by increasing its ability to develop, manufacture, and trade essential health products that help prevent, diagnose, alleviate, and cure local medical needs

Ambition

To increase manufacturing and innovation of health products (and raw material inputs) on African continent to meet 60% of demand by 2040

Strategic priorities

- A Ensure healthy markets for locally produced health products (incl., market design and intelligence)
- B Strengthen the local R&D ecosystem through facilitation of IP and tech transfer, increase of R&D capabilities and capacity
- C Support capability building and talent development to enable local manufacturing
- D Incubate and scale capacity and infrastructure of local manufacturing and supply chain
- Attract investments to drive delivery of above strategic priorities through catalyzing strategic partnerships and resources



Our 5-year roadmap aims to realize the AU's public health order across health products, expanding from the current focus on vaccines

	-	
2018 – 2022		
PAVM set-up and start		
implementation		


Objectives along 5-year roadmap

- Set-up and mandated PAVM to execute towards manufacturing 60% of local Vx demand
- **Develop continental strategy** and launch Framework for Action (FFA)
- Install Secretariat and launch implementation of priority bold program activities

2023-2028

Step-change towards self-reliant continent with local development and manufacturing

- Expand into broader health products/raw material manufacturing strategy and implementation, while scaling bold programs
- Build organizational capacity for PAVM and Harmonized Africa Health Manufacturing Platform
- Define innovation ecosystem foundation required to address priority medical unmet needs
- Continue cultivate partnerships and incentivize funding across the health ecosystem





PAVM has enabled ecosystem shifts through its strategic priorities and bold programs

		Achievements		
Strategic priorities	Bold programs	Ecosystem	23 H1 achievements	
Ensure healthy markets for locally produced health products	Market design	2 continental market shaping instruments in progress (i.e., Gavi AMC, Africa CDC PPM)	 PPM politically approved and design launched MOU signed with Gavi on AMC 	
	Regulatory strengthening	AMA treaty came into force and 5 NRAs with ML3 status (2 in producing countries)	 30mn USD dispersed and 5 NRA's supported for capacity and capability building (incl., needs assessment; implementation plan) 4 RCOREs endorsed (SAHPRA, TMDA, Ghana FDA, Egypt FDA) 	
Strengthen the local R&D ecosystem through facilitation	R&D			
of IP, tech transfer, and R&D capabilities	Tech Transfer and IP	For 10 vaccines 1+ suppliers signed or started tech transfer (incl. YF, Hexa, PCV)	Fully operationalized in 2023 H2	
Support capability building and talent development to enable local manufacturing	Talent development	~3,000 FTEs active in local vaccine manufacturing and R&D and continental strategy on training curriculum	 Manufacturing needs assessment tool launched MOU signed with IVI for \$200K sponsored training with 50+ manufacturing FTE's trained 	
Incubate and scale capacity and infrastructure of local	Infrastructure development		• Vx value chain diagnostic completed and aligned with 7+ manufacturers and other stakeholders	
manufacturing and supply chain			• Partnership established with CEPI on stakeholder engagement and roadmap development (e.g., forum, publication)	
Attract investments to drive delivery	Access to Finance	Donors and DFI's committed >1.5 Bn USD investment into continent	 Common goal and set of initiatives galvanized across African member states and stakeholders 	
	Agenda setting and coordination	9 commercial scale facilities and broader publicly announced ramp-up of manufacturer capacity (e.g., Aspen, Moderna, IPD)	 MoH convened on a regular basis on local vaccine manufacturing, 10+ meetings held 	

Short term (2023-2024) milestones need to be achieved across the ecosystem to work towards the 2040 ambition

2024 milestones for the vaccine manufacturing ecosystem	vaccine production	
237Mn doses p.a. to be produced by local manufacturers (i.e., Biovac, IPD, Vacsera, Aspen)	~1.5Bn doses to be produced in 2040	
AMC and PPM pilot set-up with MoU signed for operationalization of pilot in 2024	~15% of materials locally procured AMA 10+ NRAS operationalized with Vx with ML3 status capabilities	
 2+ RCOREs operationalized for ML3 NRA(s) to provide know-how and capability building to other NRAs 		
Additional 5+ tech transfers Initiated with increasing number of projects involving more upstream processes	*12,000 FTEs in vaccine manufacturing and R&D	
>1k of people trained through comprehensive training offering (e.g., short courses, internships, placements)		
Further ~2Bn USD attracted e.g., \$25Mn for scholarship programs		

+ Expanded scope to include broader health products (exact milestones tbd)

... to support the 2040 ambition of 60% local

THANK YOU!







PARTNERS













PANEL DISCUSSION





Zainab Aziz Associate Director- RA SSA Policy and Strategic Operations **Novartis**

Greg Perry Assistant Director General **IFPMA**



Akhona Tshangela Program coordinator PAVM



John Mwangi Head, Regulatory Affairs – East & West Central Africa Bayer




Khadijah Ade-Abolade **Deputy Director Drug Evaluation &** Research NAFDAC



Sylvia Vito Africa Head Sub-Sahara Africa & **Frontier Markets EVA PHARMA INTERNATIONAL**



Patrick Tippoo Chief Science and Innovation Officer BIOVAC **Executive Director AVMI**





Susan Winks Head of Research **Operations and Business** Development H₃D



Kirti Narsai Owner, HealthValue **Consulting**, Senior Researcher – Nelson Mandela School of Public Governance, Strategic Health Advisor – Corporate **Council on Africa**

QUESTIONS AND ANSWERS

We encourage you to use the Q&A box to raise questions to the speakers.

If a question you would like to ask has already been raised, you can also "like" that question. "





KEY TAKEAWAYS – AfRC Track 07

- Increased local production would assist in ensuring more equitable access to medicines in Africa.
- Developing a sustainable local manufacturing landscape is key and drivers of this include:
 - Private and public sector partnerships;
 - Effective funding models;
 - Strengthening and harmonising regulatory activities across the continent;
 - Building capacity in a streamlined manner.
- Securing the existing local supply chain routes to prevent counterfeiting are also equally critical.



12-15 SEPTEMBER VIRTUAL CONFERENCE

AfRC Track 08


Session Moderators: Chimwemwe Chamdimba

Head of the African Medicines Regulatory Harmonisation AUDA NEPAD

Jo Ann De Crescenzo

Senior Director, Head of Regulatory Affairs, EMEA Emerging Markets & GPH Jansen



















INTERACTIVE POLL

Join at menti.com use code 5892 2117

Mentimeter

Instructions

Go to www.menti.com

Enter the code


5892 2117





Or use QR code











AMRH Initiative and latest developments on AMA

Where are we coming from?

- 2005: AU Decision 55 on Development of the Pharmaceutical Manufacturing Plan for Africa (PMPA) within the NEPAD Framework
- 2009: Initiation of the African Medicines Regulatory Harmonisation Programme (2011 First regional project launched)
- 2012: PMPA Business Plan developed
- 2015: Executive Council Decision recognising the AMRH as the foundation of the AMA
- 2016: Adoption of the AU Model Law on Medical products regulation (broaden the focus to all products
- **2019:** Adoption of the Treaty for the establishment of the AMA



The African Medicines Regulatory Harmonization Initiative Achievements



Coordinating Regional Regulatory Platforms EAC, SADC, ECOWAS, ECCAS, IGAD from 2009 (>85% of Sub-Saharan Africa)



Reduction of registration timelines through joint review of dossier applications and inspection of manufacturing sites **Domestication of the AU Model Law for Medical Products Regulation** Adoption of the AMA Treaty by the AU Summit in February 2019 Attainment of ISO-Certification and WHO Maturity Level 3 by some NMRAs **Designation of 11 Regional Centres of Regulatory Excellence (RCOREs); Evolution of the AMRH Governance structure**

Support on COVID-19 response

Partners: the African Union Commission (AUC), the Pan African Parliament (PAP), the World Health Organization (WHO), the World Bank, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth & Development Office (FCDO)



The Africa Medicines Agency (AMA)

- Aimed at facilitating sustained continental-wide harmonization of technical standards and processes.
- Build on AMRH efforts to sustain ongoing regulatory harmonization initiatives.
- Will support countries to assess complex medical products.
- Will provide scientific and regulatory advice in support of local pharma industry development.
- Will lead to removal of unnecessary technical barriers to trade in pharmaceuticals in support of African Continental Free Trade Area (AfCFTA).



Highlights on AMA

- 26 Member Stated ratified the AMA Treaty
- AMA Treaty came into force on 5th November 2021
- Governance structures of the AMA established
 - o CoSP
 - o Bureau of the AMA
 - Ghana Chair of Bureau
 - Governing Board (being established)
- CoSP constituted and Rules of Procedure adopted.
- Host country selected and host country agreement signed
 - o **Rwanda**
- Ongoing process of recruiting the AMA DG



AMRH support to AMA operationalisation

- Provide technical support building on AMRH technical assets (as per AU Executive Council Decision)
 - Setting up Technical Committees in specialized regulatory technical areas
 - Linking with RECs on the regulatory harmonization
 - Adoption of continental technical guidelines and approval processes in key regulatory areas
 - o Piloting continental EMP and GMP
 - Supporting regulatory systems strengthening in Member States including the domestication of Model Law
 - Research and capacity building of regulator through RCORES
 - o Leading regulatory work required for the PAVM
 - o Building regulatory infrastructure e.g., IT Systems
 - o Reliance framework development
 - o Laboratory systems strengthening
 - Developing a continental plan on SF linked with RECs and MS
- Supporting participation of countries yet to ratify AMA Treaty
- Advocacy for ratification



AMRH Support to AMA

٠

٠

٠

٠



3

The African Vaccines Regulatory Forum (AVAREF)

The African Medicines Quality Forum (AMQF)

The African Blood Regulatory Forum (ABRF)

- The African Medical Devices Forum (AMDF)
- Pharmacovigilance / Safety Surveillance

Regulatory oversight on clinical trials and joint reviews of complex products including vaccines

Quality controls and market surveillance

٠

- Technical oversight on blood and blood products regulation
- Technical oversight on medical devices and invitro diagnostics regulation
- Safety monitoring of medical products

6 Good Manufacturing Practice (GMP)

- Regulatory Capacity Development (RCD)
- 8 Medicines Policy and Regulatory Reforms (MPRR)



10 Product Evaluation & Registration (PE&R)

- Inspection of manufacturing sites
- Coordination of regional centers of regulatory excellence (RCOREs)*
- Domestication of the AU Model Law on Medical Products Regulation
- Support the operationalization of regulatory information management systems (RIMS)
- Support joint reviews and marketing authorization






Regional Centres of Regulatory Excellence (RCOREs)

As part of its mandate to strengthen regulatory capacity development in Africa, the NEPAD Agency through its AMRH programme has designated **11 Regional Centres of Regulatory Excellence (RCOREs)** in **eight diff erent regulatory funct ons**









AFRICAN UNION DEVELOPMEN

The emerging continental regulatory ecosystem

- AMA will not replace RECs or NRAs it will coordinate and complement certain aspects of their work, with the majority of regulatory work still performed by RECs and NMRAs
- RECs are important coordination structures at the regional level: collaboration draws on the expertise and capacity of national authorities to undertake the work
- AMRH an important foundation for the operationalisation of AMA
- NRAs will have responsibilities for provision of expertise and technical leadership to RECs and AMA. They will also use the recommendations from their REC and from AMA to inform their own formal regulatory decisions
- Not all countries are AMA members yet. They still need to participate in regulatory harmonisation and systems strengthening – AMRH remains an important component of the ecosystem



Looking ahead.....

- Finalization of the composition of the AMA Board & DG recruitment
- Technical component of AMA building on AMRH technical work
- Continued advocacy for ratification of the AMA Treaty to reach all Member States
- Building RECs & national capacity key for successful collaboration across and regions and continent.
- Networking, information sharing and leveraging on available capacities REC platforms
 - Anchor NRAs ML 3 at the regional level to facilitate learning and mentoring through twining
 - o Benchmarking of NRAs
 - Supporting countries to implements IDPs mobilizing technical and financial support
 - Monitoring implementation and identifying bottlenecks
 - RCOREs training and research



Looking ahead..... (2)

- Work-sharing at the regional and continental level
 - Regional and continental TCs
 - Joint assessment and inspections
 - NQCL networking
- Strengthened reliance framework on regulatory decision Reliance framework
- Inter-REC learning & knowledge sharing
 - Continental harmonisation will only be successful if RECs collaborate
- Coordination, technical support, monitoring & evaluation, and learning



Thank you



12-15 SEPTEMBER VIRTUAL CONFERENCE

Keynote speech by: Samuel Asante Boateng FDA Ghana





rice















PANEL DISCUSSION



Jo Ann De Crescenzo Senior Director, Head of Regulatory Affairs EMEA Emerging Markets & GPH Jansen



Chimwemwe Chamdimba Head of the African Medicines Regulatory Harmonisation AUDA NEPAD



Victoria Palmi Reig International Affairs officer EMA



Gabriela Zenhäusern Deputy Head Stakeholder Engagement Swissmedic



Samuel Asante-Boateng Director of Drugs and Herbal medicine Registration Directorate Ghana FDA



Sakhile Dube Co-ordinator for the SADC MRH Project SADC



Mohammed Ismail Team Lead of Medicine Supply, Health Infrastructure Equipment Maintenance WHO



Uchenna Adesugba Head, RA Policy & Strategic Operations Novartis



INTERACTIVE POLL

Join at menti.com use code 5892 2117

Mentimeter

Instructions

Go to www.menti.com

Enter the code

5892 2117



Or use QR code



QUESTIONS AND ANSWERS

We encourage you to use the Q&A box to raise questions to the speakers.

If a question you would like to ask has already been raised, you can also "like" that question. "





KEY TAKEAWAYS – AfRC Track 08

- All actors and stakeholders are needed to join forces and help facilitate the use of the following best practices:
 - Transparency and reliability through the organization of joint activities,
 - Reliance to ensure equitable use of resources.
 - Harmonization of regulatory policies in line with global standards, scientific evidence-based regulatory decision making, leading to accelerated, transparent, streamlined and predictable review processes spanning the full product lifecycle
 - NRA capacity building, via Regional Centres of Regulatory Excellence (RCORES)
 - Timely communication amongst stakeholders.
 - Cooperation at levels, Improve interagency collaboration.
 - Adoption of digital and technology solutions
 - Sustainable funding mechanism.



12-15 SEPTEMBER VIRTUAL CONFERENCE

Conference Closing Remarks



Jacqueline Acquah

Associate Director, Global Public Health Vaccines Regulatory Affairs (EMEA) Johnson & Johnson IFPMA ARN Co-chair



ORGANIZER



P A R T N E R S



Inovative Pharmaceutical Association







THANK YOU!

Join on 18 September AfRC satellite session

Pharmacovigilance expertise: The importance of collaboration and learning

10:00 -13:00 CET



O R G A N I Z E R



PARTNERS



Increase a sociation South Africa





